Safety study supports clinical development of immunotherapeutic oncolytic measles vaccine

Safety study supports clinical development of immunotherapeutic oncolytic measles vaccine

Bibliographic Details
Main Author:	Christine E. Engeland
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Molecular Therapy: Methods & Clinical Development
Online Access:	http://www.sciencedirect.com/science/article/pii/S2329050122001280

Similar Items

Measles Virus as an Oncolytic Immunotherapy
by: Christine E. Engeland, et al.
Published: (2021-02-01)

Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference
by: Sophie C. Anker, et al.
Published: (2023-01-01)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
by: Stephen eThorne
Published: (2014-06-01)

Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
by: Daniel E. Meyers, et al.
Published: (2017-06-01)

Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists
by: Paul S. Backhaus, et al.
Published: (2019-10-01)

Measles to the Rescue: A Review of Oncolytic Measles Virus
by: Sarah Aref, et al.
Published: (2016-10-01)

Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory
by: Rūta Veinalde, et al.
Published: (2022-03-01)

Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites
by: Mathias Felix Leber, et al.
Published: (2018-06-01)

In Vitro Sensitivity of Neuroendocrine Neoplasms to an Armed Oncolytic Measles Vaccine Virus
by: Nikolai V. Scheicher, et al.
Published: (2024-01-01)

Starvation-Induced Differential Virotherapy Using an Oncolytic Measles Vaccine Virus
by: Gabriel Scheubeck, et al.
Published: (2019-07-01)

Measles virus: Background and oncolytic virotherapy
by: Sankhajit Bhattacharjee, et al.
Published: (2018-03-01)

Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens
by: Yong Luo, et al.
Published: (2020-01-01)

Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation
by: Rūta Veinalde, et al.
Published: (2017-04-01)

Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1
by: Markus eMoehler, et al.
Published: (2014-05-01)

Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements
by: Chae-Ok Yun, et al.
Published: (2022-08-01)

Expression of CCL19 from Oncolytic Vaccinia Enhances Immunotherapeutic Potential while Maintaining Oncolytic Activity
by: Jun Li, et al.
Published: (2012-12-01)

Advances in oncolytic virotherapy
by: Stephen J. Russell, et al.
Published: (2022-04-01)

Clinical safety issues of measles, mumps and rubella vaccines
by: M.A. Afzal, et al.
Published: (2000-01-01)

Formulation for the Targeted Delivery of a Vaccine Strain of Oncolytic Measles Virus (OMV) in Hyaluronic Acid Coated Thiolated Chitosan as a Green Nanoformulation for the Treatment of Prostate Cancer: A Viro-Immunotherapeutic Approach
by: Naseer F, et al.
Published: (2023-01-01)

Portrait of a Leader in Immunotherapeutics<subtitle>Oncolytic viruses for treatment of cancer</subtitle>
by: Akseli Hemminki
Published: (2012-08-01)

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
by: Johannes P. W. Heidbuechel, et al.
Published: (2021-04-01)

Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
by: Ahmed A. Mostafa, et al.
Published: (2018-06-01)

MECHANISMS AND CLINICAL EFFECTS OF DRUGS BASED ON ONCOLYTIC ADENOVIRUSES, HERPES VIRUSES, REOVIRUSES AND MEASLES VIRUS
by: A. P. Cherniakova, et al.
Published: (2020-12-01)

A Combined Ultrafiltration/Diafiltration Process for the Purification of Oncolytic Measles Virus
by: Daniel Loewe, et al.
Published: (2022-01-01)

Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic
by: Hai Zou, et al.
Published: (2023-01-01)

Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink
by: Kayla E. Hanson, et al.
Published: (2023-04-01)

Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
by: Assia L. Angelova, et al.
Published: (2017-12-01)

Aeration and Shear Stress Are Critical Process Parameters for the Production of Oncolytic Measles Virus
by: Tanja A. Grein, et al.
Published: (2019-04-01)

Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy
by: Mao Xia, et al.
Published: (2019-09-01)

MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
by: Miguel Ángel Muñoz-Alía, et al.
Published: (2021-02-01)

Human Vaccines & Immunotherapeutics: news
Published: (2021-01-01)

Human Vaccines & Immunotherapeutics: news
Published: (2019-08-01)

Human Vaccines & Immunotherapeutics: News
Published: (2017-03-01)

Human Vaccines & Immunotherapeutics: News
Published: (2017-04-01)

Human Vaccines & Immunotherapeutics: News
Published: (2017-11-01)

Human Vaccines & Immunotherapeutics: News
Published: (2017-08-01)

Human Vaccines & Immunotherapeutics: News
Published: (2017-07-01)

Human Vaccines & Immunotherapeutics: News
Published: (2017-01-01)

Human Vaccines & Immunotherapeutics: news
Published: (2021-02-01)

Human vaccines & immunotherapeutics: news
Published: (2021-07-01)